MAPT and Alzheimer disease: During clinical follow-up, MCI patients who progress to AD with dementia have the standard AD CSF biomarker profile (decreased CSF Aβ42 with increased T-tau and P-tau) already at this stage of the disease (Andreasen et al., 1999).